Sabine Mueller

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients Wit...

MTD is defined as the dose at which fewer than one-third of participants experience a dose limiting toxicity (DLT) for all participants who received at least one study intervention.

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...

Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.

Recruiting

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Percentage of participants alive and free from progression at 6 months after the initiation of the combination of the backbone (i.e., ONC201) with a novel agent given in the maintenance phase of therapy. The primary analysis for P...

Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Gli...

Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments when compared to archived recurrent pediatric HGG group. The number of participants with high cell cycle gene ...

Recruiting

Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Progression-free survival is defined as the time of documented response until disease progression as defined by Response assessment in neuro-oncology criteria (RANO) criteria. PFS will be reported by overall group at 12 months.

Recruiting

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

Adverse events and clinically significant laboratory abnormalities (meeting grade 3, 4, or 5 criteria according to NCI CTCAE) will be summarized by maximum intensity and relationship to study drug(s). Grade 1 and 2 adverse events ...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gl...

We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...

Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent...

A DLT is defined as a treatment-related adverse event (AE) or abnormal laboratory value that occurs in the first cycle of treatment (Cycle 1 for Arm A and D; Cycle 0 for Arm B and C), meets criteria for DLT as outlined below and i...

Recruiting

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma

Time to tissue collection will be used to determine the feasibility of using the results of real-time in vitro drug screening, WES and RNAseq of participant-derived specimens to guide treatment recommendations by a specialized tum...

Recruiting